L-Cystine
|
Basic information |
| Metabolite name | L-Cystine |
 | HMDB0000192 |
 |
C00491 |
 |
67678 |
| Synonyms | Cystine |
| No. of studies | 21 |
|
Basic information |
| Metabolite name | L-Cystine |
| HMDB0000192 |
|
C00491 |
|
67678 |
| Synonyms | Cystine |
| No. of studies | 21 |
|
Relationship between L-Cystine and depression (count: 21) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M065 | Type2 | depressed group at 6-weeks treatment vs. baseline | Plasma | Human | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Up |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M528 | Type2 | CUS + fluoxetine group vs. CUS group | Frontal cortex | FVB mouse | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Down |
| Study M823 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M881 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M906 | Type2 | after rTMS treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M909 | Type3 | ketamine group vs. control group | Hypothalamus | CD-1 mouse | Up |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |